Asklepios Biopharmaceutical Inc. (Askbio), a North Carolina-based gene therapy pioneer, has secured $235 million in fresh funding that it said will help advance and expand its clinical work, enhance its manufacturing capabilities and drive its long-term growth. TPG Capital and Vida Ventures invested $225 million for a minority stake in the company while Askbio's founders and board members added $10 million more.